Cargando…
1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)
BACKGROUND: CDI is a 2-hit process requiring C. difficile spores and antibiotic-mediated dysbiosis, a low diversity state of the gut microbiome. Recurrent CDI (rCDI) is common and may be related to inadequate antibiotic concentrations (e.g., metronidazole; MET) or persistent dysbiosis (e.g., vancomy...
Autores principales: | Ford, Christopher, Litcofsky, Kevin, McGovern, Barbara, Pardi, Darrell, Nathan, Richard, Hansen, Val, Brennan, Robert, Pullman, John, Bernardo, Patricia, Tomlinson, Amelia, Horgan, Kevin, Bryant, Jessica, Walsh, Emily, Rodriguez, Michelle, Rogalin, Henry, Wang, Elaine, Henn, Matt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809198/ http://dx.doi.org/10.1093/ofid/ofz360.1367 |
Ejemplares similares
-
653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023) -
655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023) -
Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017) -
1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
por: Ford, Christopher, et al.
Publicado: (2018) -
621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
por: Henn, Matthew, et al.
Publicado: (2018)